Tenofovir News and Research

RSS

New early phase study evaluates “on-demand” HIV prevention method for women

A fast-dissolving vaginal insert that women would use at or around the time of sex as an "on-demand" HIV prevention method is being evaluated in a new early phase study being conducted by MATRIX, a United States Agency for International Development (USAID)-funded project focused on the early research and development of innovative HIV prevention products for women.

7 Dec 2023

Major UK study finds high demand and efficacy for HIV PrEP among sexual health service attendees

HIV PrEP requirement, duration, uptake, and usage among sexual health services (SHS) attendees in England.

4 Dec 2023

Generic PrEP use could reduce new HIV acquisitions, save lives among young men who have sex with men

Anne Neilan, MD, a physician-scientist in the division of Infectious Diseases at Massachusetts General Hospital is the senior author of a recently published paper in Clinical Infectious Diseases, Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-Saving at Generic Drug Price.

12 Oct 2023

New injectable solution could help manage HIV unlike any current treatment methods

A new injectable solution that self-assembles into a gel under the right conditions could help manage HIV unlike any currently available methods, researchers have found.

25 Sep 2023

Comparing HIV PrEP medications: Study explores hypertension risk in adults on TAF vs. TDF

The risk of hypertension and statin initiation in adults starting Human Immunodeficiency Virus Pre-exposure prophylaxis.

13 Sep 2023

A peek at Big Pharma’s playbook that leaves many Americans unable to afford their drugs

America's pharmaceutical giants are suing this summer to block the federal government's first effort at drug price regulation.

18 Aug 2023

Study reveals substantial gap in PrEP access in more than one-third of New England colleges and universities

Young gay, bisexual, and other men who have sex with men (MSM), accounted for 80% of new HIV infections among youth ages 13–24 in 2018 and represents a priority population for HIV prevention.

24 Jul 2023

Medicines for All Institute at VCU receives $18.7 million grant to improve access to medicines

The Medicines for All Institute at Virginia Commonwealth University will work on 14 new global health projects and expand its capabilities to improve access to medicines around the world thanks to an $18.7 million grant from the Bill & Melinda Gates Foundation.

11 May 2023

Many top-selling brand-name drugs in Medicare may provide little added therapeutic benefit

Brand-name drugs cost two to three times more in the U.S. than in other countries, but many of the top-selling brand name drugs may provide little added therapeutic benefit.

18 Apr 2023

The decision-making process for the launch of trials for COVID-19 repurposed antivirals

Researchers reviewed the decision-making process for performing randomized clinical trials for three drugs under consideration for repurposing for COVID-19 treatment: remdesivir, molnupiravir, and tenofovir disoproxil fumarate.

30 Mar 2023

Two newer simplified HIV treatment options found to be at least as effective as the standard of care

Two newer simplified treatment options are at least as effective as current approaches, according to the results of a world-first international clinical trial into second-line HIV therapy led by the Kirby Institute at UNSW Sydney and presented today at the Conference on Retroviruses and Opportunistic Infections in Seattle.

23 Feb 2023

Use of dapivirine vaginal ring during third trimester of pregnancy poses no safety concerns

A vaginal ring containing the antiretroviral drug dapivirine posed no safety concerns when used in the third trimester of pregnancy, according to results to date from the first study of the dapivirine ring during pregnancy and one of only a few studies of an HIV prevention product in pregnant cisgender women.

20 Feb 2023

Study reports two cases of ocular MPox in HIV-infected patients

Researchers review the symptoms, diagnosis, and treatment of ocular Mpox syndrome in men living with HIV infection.

7 Feb 2023

Hepatitis B virus haplotype number is a predictive marker of functional cure during antiviral therapies

Patients with a lower hepatitis B virus haplotype number are more likely to achieve a functional cure with chronic hepatitis B treatment.

4 Dec 2022

RNA-dependent RNA polymerase inhibitors in COVID-19 therapy

A new paper reviews current knowledge of RdRp inhibitors that could be developed further to provide broadly effective antivirals against SARS-CoV-2 in particular and CoVs in general.

10 Oct 2022

Monkeypox virus infection in an immunocompromised patient

Researchers assessed the manifestations of the monkeypox infection in an immunocompromised patient.

19 Sep 2022

FDA approval of long-acting injectable drug marks a vital expansion of HIV prevention options

Yesterday the U.S. Food and Drug Administration announced its first approval of a long-acting HIV prevention medication. Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected once every two months.

21 Dec 2021

Scientists now close to eliminating mother-baby HIV transmission, says leading researcher

Quarraisha Abdool Karim has spent the past three decades studying HIV and AIDS. She has become one of the world's leading epidemiologists and made major contributions to the global understanding of how HIV affects young women.

24 Nov 2021

Hepatitis B in newborns is a public health issue in the Pacific islands

The Pacific island nations are falling back on immunization targets, especially those for diseases spread through mother-to-child transmission, according to WHO officials.

24 Sep 2021

Electronic health systems helped increase HBV screenings during COVID-19 pandemic

At the beginning of the COVID-19 pandemic, community health clinics saw a significant drop in patient visits. Important screenings like those for the hepatitis B virus (HBV) were getting missed, which was a setback for a local program called END B to end the transmission of HBV - a leading risk factor for liver cancer.

23 Aug 2021